IMV Inc. announced initial patient data from the VITALIZE Phase 2B trial evaluating its lead DPX product, MVP-S, in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma who received at least three previous lines of treatment. Detailed results will be presented in a podium presentation at the Immuno-Oncology 360 degrees conference to be held in New York City on February 7-10, 2023.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMV:
- IMV Blasts Up after New Test Data Emerges
- IMV begins trading on the TSX and Nasdaq post-reverse stock split
- IMV Inc. shareholders approve reverse stock split at 88%
- IMV Inc. reports Q3 EPS (11c), consensus (15c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue